The majority of them were diagnosed with invasive ductal carcinomas (88.6%, n = 247), out of which most were hormone receptor-positive (86.5%, n = 244) and HER-2/neu negative (85.8%, n = 242). Here, ERBB2 is linked to invasive ductal breast carcinoma.